Proqr Therapeutics (PRQR) Stock Price, Quote & News

Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Re...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 88 166 7000

Website: www.proqr.com

Address:

Zernikedreef 9, Leiden, Netherlands

LeftyT Nov. 13 at 8:59 PM

$PRQR I picked up 500 sh at 2.11 today. Scratching my head wondering why this isn't moving up.

1 · Reply

ehpats Nov. 13 at 6:02 PM

$PRQR maybe investors thinking korro editing doesn’t work so Prqr might not work? 🤷

0 · Reply

ehpats Nov. 13 at 5:27 PM

$PRQR expected a little more interest today. Timing of all this news being good for Prqr.

0 · Reply

dirkfrank Nov. 13 at 4:12 PM

$PRQR doesn’t seem to sink into the market yet

0 · Reply

biochirp Nov. 13 at 3:20 PM

$KRRO dump Korro and buy $PRQR 🙌

0 · Reply

biochirp Nov. 13 at 2:30 PM

$PRQR to Lilly or Novo👀

0 · Reply

justfacts1 Nov. 13 at 7:25 AM

$PRQR

0 · Reply

biochirp Nov. 13 at 3:40 AM

$PRQR $KRRO news is good, puts ProQR in the number two spot for RNA editing now

1 · Reply

johnnygogogo Nov. 13 at 12:11 AM

$PRQR was smart to make the delivery switch to Galnac from LNP when they did, and also not to choose the most crowded indication ever (AAT) as their lead attempt. See KRRO and WVE

2 · Reply

bowlerhatsftw Nov. 9 at 3:48 PM

$PRQR PRQR

1 · Reply

ProQR Announces Third Quarter 2025 Operating and Financial Results

Nov 3, 2025, 6:46 PM EST - 11 days ago

ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript

Oct 20, 2025, 8:00 AM EDT - 25 days ago

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

Oct 13, 2025, 8:30 AM EDT - 4 weeks ago

ProQR to Participate in Upcoming Investor Conferences in October 2025

Aug 7, 2025, 7:00 AM EDT - 3 months ago

ProQR Announces Second Quarter 2025 Operating and Financial Results

Jul 28, 2025, 8:00 AM EDT - 3 months ago

ProQR Announces Upcoming Presentation at RNA Editing Summit

Jun 26, 2025, 4:30 PM EDT - 5 months ago

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

May 12, 2025, 8:00 AM EDT - 6 months ago

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

May 8, 2025, 7:00 AM EDT - 6 months ago

ProQR Announces First Quarter 2025 Operating and Financial Results

May 2, 2025, 8:00 AM EDT - 7 months ago

ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

May 1, 2025, 8:00 AM EDT - 7 months ago

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

Apr 14, 2025, 7:00 AM EDT - 7 months ago

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

Mar 13, 2025, 7:00 AM EDT - 8 months ago

ProQR Announces Year End 2024 Operating and Financial Results

Dec 10, 2024, 8:00 AM EST - 1 year ago

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

Oct 25, 2024, 4:45 PM EDT - 1 year ago

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

Oct 22, 2024, 10:15 PM EDT - 1 year ago

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

Oct 22, 2024, 4:01 PM EDT - 1 year ago

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Oct 7, 2024, 8:00 AM EDT - 1 year ago

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Sep 10, 2024, 4:30 PM EDT - 1 year ago

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

May 11, 2024, 5:57 PM EDT - 1 year ago

ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)

May 9, 2024, 7:00 AM EDT - 1 year ago

ProQR Announces First Quarter 2024 Operating and Financial Results

Apr 23, 2024, 7:00 AM EDT - 1 year ago

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

Apr 22, 2024, 4:31 PM EDT - 1 year ago

ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting

Apr 19, 2024, 7:00 AM EDT - 1 year ago

ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

Mar 13, 2024, 7:00 AM EDT - 1 year ago

ProQR Announces Year End 2023 Operating and Financial Results

Jan 19, 2024, 7:00 AM EST - 1 year ago

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

Jan 5, 2024, 7:00 AM EST - 2 years ago

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

Dec 8, 2023, 7:30 AM EST - 2 years ago

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

Nov 7, 2023, 7:00 AM EST - 2 years ago

ProQR Announces Third Quarter 2023 Operating and Financial Results

Nov 6, 2023, 7:00 AM EST - 2 years ago

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

Sep 28, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

Sep 7, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 7:00 AM EDT - 2 years ago

ProQR Announces Second Quarter 2023 Operating and Financial Results

Aug 1, 2023, 7:00 AM EDT - 2 years ago

ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets

Jul 9, 2023, 6:53 AM EDT - 2 years ago

ProQR: Too Many Failures For Its RNA Technology

Jul 6, 2023, 7:00 AM EDT - 2 years ago

ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

May 9, 2023, 8:00 AM EDT - 2 years ago

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

Apr 20, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Upcoming Investor Conferences in April and May

Apr 18, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

Mar 29, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

Mar 14, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

Mar 7, 2023, 8:00 AM EST - 2 years ago

ProQR to Present at Upcoming Scientific and Industry Conferences

Dec 22, 2022, 9:12 AM EST - 3 years ago

ProQR's stock jumps on expanded RNA deal with Lilly

LLY

Dec 22, 2022, 6:15 AM EST - 3 years ago

ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform

Dec 22, 2022, 6:00 AM EST - 3 years ago

Lilly and ProQR to Expand RNA Editing Collaboration

LLY

Nov 14, 2022, 4:30 PM EST - 3 years ago

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022

Nov 9, 2022, 7:00 AM EST - 3 years ago

ProQR Announces Third Quarter 2022 Operating and Financial Results

Aug 11, 2022, 7:00 AM EDT - 3 years ago

ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

Jun 1, 2022, 7:00 AM EDT - 3 years ago

ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates

May 9, 2022, 7:00 AM EDT - 3 years ago

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022

LeftyT Nov. 13 at 8:59 PM

$PRQR I picked up 500 sh at 2.11 today. Scratching my head wondering why this isn't moving up.

1 · Reply

ehpats Nov. 13 at 6:02 PM

$PRQR maybe investors thinking korro editing doesn’t work so Prqr might not work? 🤷

0 · Reply

ehpats Nov. 13 at 5:27 PM

$PRQR expected a little more interest today. Timing of all this news being good for Prqr.

0 · Reply

dirkfrank Nov. 13 at 4:12 PM

$PRQR doesn’t seem to sink into the market yet

0 · Reply

biochirp Nov. 13 at 3:20 PM

$KRRO dump Korro and buy $PRQR 🙌

0 · Reply

biochirp Nov. 13 at 2:30 PM

$PRQR to Lilly or Novo👀

0 · Reply

justfacts1 Nov. 13 at 7:25 AM

$PRQR

0 · Reply

biochirp Nov. 13 at 3:40 AM

$PRQR $KRRO news is good, puts ProQR in the number two spot for RNA editing now

1 · Reply

johnnygogogo Nov. 13 at 12:11 AM

$PRQR was smart to make the delivery switch to Galnac from LNP when they did, and also not to choose the most crowded indication ever (AAT) as their lead attempt. See KRRO and WVE

2 · Reply

bowlerhatsftw Nov. 9 at 3:48 PM

$PRQR PRQR

1 · Reply

ehpats Nov. 7 at 7:59 PM

$PRQR added at $2.12 hopefully we’ve seen the low point earlier today. 🤷

1 · Reply

Universaal Nov. 7 at 12:48 AM

$PRQR please move on guys invest in INTC you will be millionaire in few years

1 · Reply

Universaal Nov. 7 at 12:47 AM

$PRQR piece of shyt

0 · Reply

dirkfrank Nov. 6 at 10:03 PM

$PRQR back to the level of 3 months ago within a week’s time.

3 · Reply

justfacts1 Nov. 5 at 4:52 PM

$PRQR time to add.

0 · Reply

FutureInvesting777 Nov. 5 at 3:23 PM

$PRQR it is only the grail for now.

1 · Reply

dirkfrank Nov. 4 at 11:20 PM

$PRQR a very big disappointment

1 · Reply

FutureInvesting777 Nov. 4 at 8:42 PM

$PRQR is all the excitement done for 2025 ?

2 · Reply

FutureInvesting777 Nov. 4 at 8:08 PM

$PRQR will we see 2 and below before this moves in 2026?

0 · Reply

justfacts1 Nov. 4 at 1:47 PM

$PRQR

0 · Reply

justfacts1 Nov. 4 at 1:45 PM

$PRQR

0 · Reply

justfacts1 Nov. 4 at 1:43 PM

$PRQR Bottom line: The next major $PRQR value inflection won’t come from liver data alone it will come from CNS validation, proving Axiomer works in both liver and brain. Two INDs in 2026 could turn ProQR into a multi-system RNA-editing platform.

0 · Reply

Market Cap	227.26M
Revenue (ttm)	20.46M
Net Income (ttm)	-30.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-146.82%
Debt to Equity Ratio	0.08

Volume	302,000
Avg Vol	485,738
Day's Range	N/A - N/A
Shares Out	105.21M
Stochastic %K	29%
Beta	0.16
Analysts	Strong Sell
Price Target	$8.88